Pharma's $2 Trillion Moonshot Has One Giant Asterisk
Evaluate's new forecast says global drug sales will double to $2 trillion by 2032, powered by GLP-1 obesity drugs and inflammation therapies. But Wall Street has already started cutting its estimates, and the pricing math might not add up.
The Number That Turned Heads
According to a new forecast from Evaluate, the industry is set to add its next trillion in just fourteen years.
Evaluate's World Preview 2026 projects that worldwide prescription drug sales will surpass $2 trillion by 2032, growing at a compound annual rate above 7%. That's not a typo. The same market that barely cracked a trillion around 2020 is now expected to double before most of today's kindergartners finish high school.
But dig past the headline, and a more complicated story emerges: one about blockbuster obesity drugs, a shifting global map, and a pricing environment that could deflate the whole balloon.
The GLP-1 Growth Engine (and Its Speed Limit)
The single biggest driver of that $2 trillion figure? Obesity and diabetes drugs, specifically the class known as GLP-1 receptor agonists. Think Ozempic, Wegovy, Mounjaro, and Zepbound. If those names sound familiar, it's because they've become cultural phenomena, not just medicines.
Evaluate expects Eli Lilly's tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) to blow past $70 billion in annual sales by 2032. That would make it the largest-selling drug in history. For context, Luxembourg's GDP is roughly $90 billion — packed into a single injectable pen.
The report also predicts that five individual drugs will each top $20 billion in sales, and the top twenty products will account for nearly one-fifth of the entire global market. Concentration like that hasn't been seen before.
But Wall Street's enthusiasm for GLP-1s has cooled considerably since the "peak hype" days of 2023. Goldman Sachs cut its 2030 obesity drug market forecast from $130 billion down to roughly $95–105 billion. Jefferies went further, slashing its peak estimate by about 20% to $80 billion. The reason? A cocktail of price erosion, payer pushback, and a flood of competitors lining up to enter the market.
Morningstar expects the average global annual price for GLP-1 obesity therapy to as competition intensifies. Goldman Sachs bakes in about 7% annual price erosion and calls U.S. pricing "the single biggest swing factor" for the entire obesity drug market.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
drop from around $5,400 to roughly $2,800 by 2032
The Persistence Problem Nobody Likes to Talk About
There's another wrinkle that doesn't show up in rosy sales projections: patients keep quitting.
Goldman Sachs survey data shows that cost and loss of insurance coverage account for roughly 60–64% of treatment discontinuations among obesity drug users. Side effects (mostly GI issues) explain only about 15%. In other words, the drugs work, but people can't afford to stay on them.
Medicare coverage for obesity drugs remains a coin flip. Goldman previously assumed a 70% chance of Medicare stepping in, based on strong cardiovascular data from clinical trials. They've since dropped that to 50/50, citing a changed political landscape and stubborn payer dynamics. Without that "Medicare unlock," tens of millions of eligible patients stay on the sidelines.
Inflammation: The Quiet Cash Machine
While GLP-1s grab headlines, another therapeutic area is quietly generating enormous revenue. Evaluate flags immunomodulators (drugs that dial the immune system up or down) as the other major growth engine, forecasting roughly 10% annual growth through 2032.
The inflammatory disease biologics market was worth about $99 billion in 2024. TNF inhibitors, the oldest class in the bunch, still hold roughly 41% of that pie. Newer drugs targeting IL-17 and IL-23 (proteins involved in conditions like psoriasis and inflammatory bowel disease) are gaining share fast, while JAK inhibitors, a newer class of oral pills, represent about 18% and are growing even faster.
Think of it like a relay race. TNF drugs ran the first leg and built a massive lead. Now IL-17/23 biologics are sprinting the second leg, and JAK inhibitors are waiting for the handoff. The overall inflammatory biologics market could reach $145–157 billion by the early 2030s, according to DataM Intelligence.
China Enters the Chat
The Evaluate report also spotlights China's biopharma market as a strategic growth driver. China's total pharmaceutical market hit roughly $329 billion in 2025, and industry forecasts peg it at nearly $600 billion by 2034, growing at about 6.6% per year.
The real action is in biologics. China's biologics segment is projected to grow at 8–10% annually through the early 2030s, outpacing the country's overall pharma growth by a wide margin. Investment in manufacturing infrastructure tells the story: China's single-use bioprocessing market (the equipment used to make biologics) is growing at a blistering 18% CAGR through 2032.
China already runs almost 40% of all Phase I clinical trials globally. It's becoming a hub not just for consumption, but for early-stage drug development and licensing deals.
The Patent Cliff Elephant
Evaluate's forecast includes a sobering counterweight. The pharmaceutical equivalent of a dam breaking is approaching; revenue from older blockbusters will flood out as patents expire between 2026 and 2032, and companies must replace it with new launches just to stay even.
This dynamic will fuel M&A activity. Companies sitting on expiring patents will need to buy their way into growth, particularly in obesity, immunology, and oncology. The report positions the "second wave" of patent cliffs as a catalyst for intensified dealmaking across the industry.
Is $2 Trillion Actually Realistic?
The honest answer: it depends on what happens with pricing.
The bull case is straightforward. GLP-1 obesity drugs keep expanding (oral versions from both Novo Nordisk and Lilly are already hitting the market), inflammatory disease therapies grow steadily, China scales up, and oncology continues its march. Stack all of that together, and $2 trillion is very achievable.
The bear case focuses on the denominator. Price erosion in GLP-1s, restrictive payer policies, patient discontinuation, and a tsunami of generics from patent cliffs could all slow revenue growth. Analysts have already cut obesity market forecasts by 20–30% from their peaks. If pricing pressure is worse than expected, the $2 trillion milestone could slide to 2034 or later.
J.P. Morgan's $200 billion incretin market forecast by 2030 and Morgan Stanley's $190 billion view for diabetes plus obesity by 2035 both support the directional thesis. But Evaluate's own report wisely flags U.S. policy uncertainty, pricing tumult, and competitive crowding as material risks.
The pharmaceutical industry is about to enter its most lucrative decade ever. The question isn't whether $2 trillion is possible. It's whether the industry can outrun the forces pulling it back down to earth.
4 min read
BMS Is Printing Money Right Now. The Clock Is Ticking.
Bristol Myers Squibb just crushed Q2 estimates and hiked its 2026 forecast by billions, thanks to a blood thinner that won't quit and a new drug lineup firing on all cylinders. There's just one problem: the biggest patent cliff in pharma history is about 18 months away.
